Nebivolol is a third generation β-blocker which is a newer cardioselective beta blocking agent that is highly selective for the β1-adrenoceptor. Nebivolol is lipophylic in nature. It is devoid of intrinsic sympothomimetic or membrane stabilizing action and it also has vasodilatory effects. In addition, nebivolol also has reported as an antioxidant, anti-inflammation, cholesterol lowering action, anticonvulsant action, inhibition of apoptosis and protective effect on gastric ulcer. Alzheimer disease is one of the major neurodegenerative disorders, which affects more than 5 million people in India. Alzheimer disease (AD) is characterized by progressive loss of cognition, language and behavioural function. Oxidative stress is thought to be important early in AD progression because it is temporally linked to the development of amyloid beta (Aβ) protein in Senile Plaques and accumulation of tau protein filament in Neurofibrilary Tangles (NFT). The Aβ protein induced lipid peroxidation and generates Reactive oxygen species. Hence, in AD, the free radical and inflammatory mechanism plays a major role. The present study reveals that the Nebivolol has a protective effect on scopolamine induced Alzheimer Disease. The result has shown that the Nebivolol abolished the scopolamine induced memory deficit from the behavioural and biochemical parameters. This effect may be attributed to its potential antioxidant effect by scavenging the free radical generations.